A study of the effect of Synbiotic Supplement in Gastrointestinal Symptoms and Quality of Life in Patient with Celiac Disease: a randomized double blinded clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210717051916N1

Enrollment

108

Registered

2022-04-23

Start date

2022-05-22

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with celiac disease. Celiac disease

Interventions

Intervention group: To individuals in the intervention group, Familact synbiotic capsules are given from Zist Takhmir pharmaceutical company. each capsule of which contains 500 mg of synbiotic product

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Definitive diagnosis of celiac disease based on test results and specialist diagnosis

Exclusion criteria

Exclusion criteria: pregnancy- Breastfeeding

Design outcomes

Primary

Measure	Time frame
Gastrointestinal symptoms of patients before and after taking the supplement. Timepoint: At the beginning of the study (before the intervention) and 12 weeks later. Method of measurement: Gastrointestinal Symptom Rating Scale questionnaire (GSRS).	—

Secondary

Measure	Time frame
Quality of life of patients. Timepoint: At the beginning of the study (before the intervention) and 12 weeks later. Method of measurement: The celiac disease quality of life questionnaire (CDQOL).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Zobeiri

Kermanshah University of Medical Sciences

mehdizobeiri@yahoo.com+98 83 3427 6300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026